

Jan 20, 2025

Nobelpharma Co., Ltd.

Price agreement for HYFTOR 2mg/g gel (sirolimus) in Germany

Nobelpharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Managing Director & CEO: Mr. Jin Shiomura) announced that its European subsidiary Plusultra pharma GmbH (Duesseldorf, Germany Managing Director: Takahiro Yamasaki) product HYFTOR 2mg/g gel (sirolimus), has been evaluated by the Joint Federal Committee of German public health agencies (G-BA) in a health technology assessment. The additional benefit is confirmed for the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 years and older *.

Now the price negotiations with the German National Health Insurance Association (GKV-SV) were successfully concluded as well.

We are determined to continue contributing to society by providing critical but neglected pharmaceuticals and medical devices.

*: The indications for which it has been approved in Japan is skin lesions associated with tuberous sclerosis complex.

[Contact for inquiries]

Noboru Kudo, Head of Communications

Nobelpharma Co., Ltd.

1-17-24, Shinkawa, Chuo-ku, Tokyo 104-0033

Tel: 03-6670-3800